Sponsor Deadline
Posted: 4/14/2022

Conquer Cancer Foundation -- ASCO Registry Melanoma Research Grant

With support from the Melanoma Research Foundation (MRF), Conquer Cancer, the ASCO Foundation, has established a new grants program to foster research that uses data derived from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry (the “ASCO Registry”) to inform the cancer community about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The grant award will provide funding and access to deidentified ASCO Registry data for melanoma focused research. 

The award provides funding to qualified clinical oncology, health services, or data science researchers to support the rapid analysis of ASCO Registry data for melanoma focused research, manuscript development, and the dissemination of findings into high-impact scientific, peer-reviewed manuscripts. Rapid discovery and translation of data into knowledge, as well as the dissemination and potential for implementation of evidence, are key to these efforts as the pandemic continues to impact patients with cancer. 

The COVID-19 pandemic presents a unique opportunity to capture information on how a disease outbreak affects delivery of high-quality cancer care. While other entities have launched COVID-19 cancer registries, a majority of patients entered into the ASCO Registry are being treated at oncology practices that are independently operated or part of hospitals or health systems, rather than academic practices. ASCO’s registry collects information about patients undergoing treatment for cancer and with confirmed COVID-19 infection based on a positive test. As of March 7, 2022, the ASCO Registry has over 5,700 patients from 67 practices, with 82 patients with melanoma (see dashboard for a summary of the ASCO Registry population characteristics, including demographic and clinical factors at the time of patient enrollment to the ASCO Registry).

Deadline: May 9, 2022

Eligibility Requirements

he Research Team must meet the following criteria: 

  • Includes at least one oncology clinician who currently treats patients with melanoma AND at least one data scientist/biostatistician. (Involvement of an infectious disease clinician or scientist, while optional, is encouraged.)
  • The primary applicant/principal investigator (PI) must hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD) at the time of grant submission and may be an oncology clinician or data scientist/biostatistician as listed above.
  • The PI must be an ASCO member or have submitted a membership application with the grant application. (To apply for new membership, or to renew an existing membership, go to asco.org/membership.)
  • All members of the Research Team must be physically located in the U.S.
  • All members of the Research Team must be able to comply with the conditions of the Data Use Agreement.

The Sponsoring Institution* must meet the following criteria:

1. The Sponsoring Institution will administer the grant funds for the sole purpose of the project.

2. Applications may be submitted from the following entities:

  • Higher Education Institutions
  • Research Organizations
  • Government Organizations (may include medical centers and hospitals that have access to resources and infrastructure to support a research project)
  • Non-profit Organizations (includes medical societies or associations, advocacy organizations, foundations, hospitals)
  • Non-Governmental Organizations.

3. The Sponsoring Institution must be based in the U.S.

4. The Sponsoring Institution must be able to comply with the conditions of the Data Use Agreement.

Funding Type